




MDxHealth

Delivering Molecular Diagnostic Solutions for Urologic Cancer



INVESTOR NEWSLETTER

June 2016

MDxHealth Investor Newsletter at a glance

LETTER FROM THE CEO 

Q&A WITH PROF. DR. FRANS DEBRUYNE 

UPCOMING EVENTS AND CONFERENCES 

CONTACT 

LETTER FROM THE CEO

DEAR SHAREHOLDERS,

It is my great pleasure to provide you with a brief summary of what has been a strong first half of 2016 for MDxHealth.

During this period we were excited to announce a major milestone for the Company with the inclusion of the ConfirmMDx® for Prostate Cancer test in the prestigious US National Comprehensive Cancer Network (NCCN) Guidelines for Early Prostate Cancer Detection. The NCCN guidelines establish ConfirmMDx as a 'standard of care' for the management of men at risk for undetected prostate cancer and will have a significant impact in terms of driving market adoption and reimbursement for the Company.

Additionally, during the 1st quarter of 2016 we launched SelectMDx™ for Prostate Cancer, our new non-invasive 'liquid biopsy' test, as our second commercial product in the United States. As previously reported, the SelectMDx test was launched in Europe in the 4th quarter of 2015. To support this launch we have expanded our managed care team, positioning MDxHealth for continued revenue growth in 2016 and beyond.

In March, we were also delighted to announce our collaboration with Andros Men's Health Clinic, an established leader for aging men's healthcare in The Netherlands. As part of the collaboration, SelectMDx testing will be offered as part of a comprehensive prostate cancer testing panel for men considered at risk for the disease. The Andros Clinic has established a strong reputation with a focus on improving patient care and outcomes, and therefore makes an ideal partner to help us raise awareness and expand access to SelectMDx within the urology community. You can learn more about our collaboration with the Andros Men's Health Clinic in an interview with Prof (emeritus) Dr. Frans Debruyne, Medical Director and Co-Founder of the clinic, later in this newsletter.

Along with MDxHealth's commercial growth and market adoption of our lead product, ConfirmMDx® for Prostate Cancer, we continue to generate meaningful data that validate our tests and demonstrate clinical utility. Since the start of the year we have presented data supporting our products in some of the most respected peer-reviewed journals and industry congresses in the sector, including the

Journal of Urology, European Urology, the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and at the annual meeting of the American Urology Association.

More recently, we have also entered into a collaboration with Qiagen and granted them a worldwide license for our patented methylation-specific PCR (MSP) technology for use in their new CE-marked QIASure assay to determine cervical cancer risk, as well as an agreement with Duke University Health System regarding the use of our ConfirmMDx® for Prostate Cancer test. On top of all that, we have been awarded the 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award.

On June 14th we hosted a Capital Markets Day in New York where we provided an overview of company operations, including the commercial status of its ConfirmMDx® for Prostate Cancer and SelectMDx™ for Prostate Cancer tests and an R&D review that highlighted AssureMDx™ for Bladder cancer. The event was very well attended and guest speakers included E. David Crawford, MD, Head of Urologic

Oncology at the University of Colorado Denver (UCD), and Neal Shore, MD, Director CPI, Carolina Urologic Research Center, Myrtle Beach, South Carolina and President Elect of the Large Urology Group Practice Association. A webcast replay of the event is now available on our investor [website](#).

Our strong operational progress has been underpinned by solid fiscal performance, as reported in our 2015 full year and 2016 Q1 financial reports. We reported a sharp increase in sales, a 66 % revenue growth driven by five new payor contracts and a narrowing of losses compared to the previous year, putting us on track towards profitability. Our commercial success through the first part of the year demonstrates our ability to effectively execute on our strategy and I firmly believe that we are well positioned to become the global leader in molecular diagnostic solutions for urologic oncology.

Sincerely,

Dr Jan Groen
President and CEO



KEY HIGHLIGHTS



SelectMDx™ for Prostate Cancer US Launch



In March, we announced our collaboration with **Andros Men's Health Clinic**, an established leader for aging men's healthcare in The Netherlands



We have been awarded the 2016 Frost & Sullivan **Global Prostate Cancer Diagnostics Technology Innovation Award**.

Q&A WITH PROF. (EMERITUS) DR. FRANS DEBRUYNE, Medical Director and Co-Founder of the Andros Men's Health Clinic (Andros Mannenkliniek)

Could you tell us more about the recently launched Andros Centre for Prostate Cancer program?

Every six minutes, somewhere in the world someone dies of prostate cancer. Prostate cancer is particularly difficult to diagnose, as there are often no symptoms during the early stages of the disease. In January 2016, we launched the Andros Centre for Prostate Cancer diagnostics in Amsterdam as we felt that newer and more precise innovative diagnostic techniques, such as the SelectMDx™ for Prostate Cancer test, should be made available to the public.

Diagnosis of prostate cancer typically starts with the patient visiting his Primary Care Physician (PCP). Depending on family history, or prostate conditions, the GP will perform a simple blood test to determine if the patient has increased PSA (Prostate-Specific Antigen) levels in the blood. Increased PSA levels could be an indication of increased risk for prostate cancer, and requires further examination by a urologist.

This is where the SelectMDx™ for Prostate Cancer test plays a vital role. In the case of increased PSA levels in the blood, the urologist may recommend an MRI scan or even a prostate biopsy. However, data suggests an increased rate of complications associated with invasive prostate biopsy procedures, with as many as 18% of men reporting some complications and up to 3% of men being hospitalized in the 30 days following a biopsy. The SelectMDx test can help differentiate men at high risk for aggressive prostate cancer who would benefit most from an MRI and prostate biopsy, compared to men at very low risk who could avoid a biopsy. If the patient's SelectMDx test result indicates a high risk for aggressive prostate cancer, the urologist will then perform a physical examination, an echography of the prostate and likely an MRI-guided prostate biopsy.

How does the SelectMDx test compare to the other tests you offer, including PSA and MRI?

There are several benign (non-cancerous) prostate related conditions that may affect PSA levels, so the challenge is to identify the subset of men whose elevated PSA level is caused by prostate cancer, which is generally around 25% of cases. The SelectMDx test provides a low-cost, non-invasive means to assess a patient's risk for aggressive prostate cancer and delivers a 98% negative predictive value to rule out high-grade cancer, improving patient selection for MRI and prostate biopsy. For men with SelectMDx results suggesting risk for aggressive cancer, an MRI-guided biopsy can enhance the accuracy of the procedure over a standard ultrasound guided biopsy, with the combination of the positive test and MRI being more cost effective than a random biopsy approach, allowing for earlier diagnosis of prostate cancer and improved outcomes.

How does the test work and what are the important benefits for the patient?

Early detection of prostate cancer remains the most critical element for overall survival, with 98.9% of those men diagnosed with low-grade cancer alive in 5 years, as compared to only 28% of men diagnosed with later stage aggressive disease. The SelectMDx test provides a quick and easy method to collect a urine sample from the patient to assess his need for a prostate biopsy. The test can aid in early detection and therefore provide the opportunity for curative intervention when the cancer is still in its earlier stages. Additionally, the test can be used as a non-invasive way to assess a patient's need for repeat biopsy. Studies have shown that prostate biopsies miss upwards of 20-30% of prostate cancers, with many of those patients harbouring potentially lethal disease. Fear of missed cancer leads to many men receiving multiple biopsies, so SelectMDx can help improve the selection of patients who need a repeat biopsy and potentially treatment.

“ SelectMDx test provides a low-cost, non-invasive means to assess a patient's risk for aggressive prostate cancer ”

UPCOMING EVENTS AND CONFERENCES

Rodman & Renshaw Annual Healthcare Conference

New York, 11 – 13 September 2016



FT Latin America Healthcare & Life Sciences Summit

Miami, 25 October 2016



Jefferies 2016 Healthcare Conference

London (16 – 17 November)



FINANCIAL CALENDAR

Publication H1 results: August 18, 2016



Publication Q3 results: November 3, 2016



IN THE MEDIA

The Wall Street Journal – A Better Prostate-Cancer Test?



VFB interview – Nog eens: wij zijn geen biotechbedrijf maar een diagnosticabedrijf



Financial Times – Oncology takes lead in exploring potential of epigenetics



Inside Beleggen interview (p. 5 – 22 March 2016)



KBC Bolero video interview





CONTACT INFO

This Newsletter is made especially for you.
Do you have any suggestions or remarks?
Please let us know: info@mdxhealth.com

Do you want to share the info with a colleague or a friend? Feel free to forward our Newsletter or suggest they subscribe via our website www.mdxhealth.com

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.

MDxHealth

EU Headquarters

CAP Business Center
Rue d'Abhooz, 31
4040 Herstal
BELGIUM
T: +32 (0)4 364 20 70
F: +32 (0)4 364 20 71
VAT: BE 0479 292 440

US Headquarters

15279 Alton Parkway
Suite 100
Irvine, CA 92618
USA
T: +1 949 812 6979
Toll Free: +1 866 259 5644
F: +1 949 242 2960

The Netherlands

Geert Grooteplein Zuid 34
6525 GA Nijmegen
THE NETHERLANDS
T: +31 (0) 24 327 9494
F: +31 (0) 24 327 9081

Email: info@mdxhealth.com
www.mdxhealth.com

